CLLS
Cellectis SA
NASDAQ: CLLS · HEALTHCARE · BIOTECHNOLOGY
$3.90
+4.56% today
Updated 2026-04-30
Market cap
$391.30M
P/E ratio
—
P/S ratio
4.92x
EPS (TTM)
$-0.67
Dividend yield
—
52W range
$1 – $5
Volume
0.0M
Cellectis SA (CLLS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-84.90%
Operating margin
-142.10%
ROE
-65.30%
ROA
-5.84%
Debt/equity
0.37x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2007 | $4.10M | $-4.36M | 63.99% | -189.73% | -106.22% |
| 2008 | $14.77M | $185149.00 | 89.56% | -32.48% | 1.25% |
| 2009 | $17.32M | $-5.52M | 86.57% | -77.92% | -31.87% |
| 2010 | $20.98M | $-10.72M | 90.84% | -72.68% | -51.11% |
| 2011 | $20.73M | $-30.90M | 84.27% | -122.09% | -149.05% |
| 2012 | $27.81M | $-29.45M | 92.70% | -93.98% | -105.89% |
| 2013 | $22.82M | $-84.28M | 96.28% | -353.35% | -369.38% |
| 2014 | $26.30M | $24320.00 | 85.97% | -24.25% | 0.09% |
| 2015 | $55.04M | $-22.46M | 95.08% | -55.46% | -40.81% |
| 2016 | $42.58M | $-63.92M | 96.04% | -150.20% | -150.10% |
| 2017 | $25.19M | $-99.37M | 89.60% | -367.83% | -394.51% |
| 2018 | $12.73M | $-78.69M | 78.49% | -825.47% | -618.12% |
| 2019 | $15.19M | $-90.69M | 25.00% | -813.38% | -597.01% |
| 2020 | $73.95M | $-72.57M | 50.95% | -115.54% | -98.14% |
| 2021 | $73.95M | $-86.28M | 50.95% | -115.54% | -116.68% |
| 2022 | $19.17M | $-98.69M | 90.76% | -467.72% | -514.78% |
| 2023 | $755000.00 | $-101.06M | -882.65% | -12,887.68% | -13,385.30% |
| 2024 | $41.51M | $-36.76M | 77.88% | -143.48% | -88.57% |
| 2025 | $73.17M | $-67.80M | 72.50% | -55.32% | -92.66% |